To verify whether ZVI-NP treatment-induced anti-tumor effects were attributed to downregulation of the NRF2 pathway and ferroptotic lipid peroxidation in vivo, overexpression of NRF2 or Liproxstatin-1 treatment were conducted in H460 subcutaneous xenograft model treated with or without ZVI@CMC NPs. This evidence concerns the gene NFE2L2 and neoplasm.